Company Overview and News

 
HZNP / Horizon Pharma plc null

2018-09-13 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
HZNP

126
Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

2018-09-07 seekingalpha - 3
Discussion: On September 4, Recro Pharma (REPH) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the company now plans to submit a revised NDA by the end of this month. Suggestions offered by the FDA now guides the company to include revised labelling language and further information on extractable and leachable items.
DOVA MNKD SYBX TSRO REDIF AST OPK RDHL PBYI ZGNX SNGX DVAX ADRO ALXN BIIB AGLE EIGR HZNP EYEG HSDT CHEK EYEGW SNY BCRX SAGE REPH JNJ UTHR APLS

 
Horizon Pharma (HZNP) Down 1.9% Since Last Earnings Report: Can It Rebound?

2018-09-07 zacks
It has been about a month since the last earnings report for Horizon Pharma (HZNP - Free Report) . Shares have lost about 1.9% in that time frame, underperforming the S&P 500.
ALLY TGI KORS HZNP

2
Horizon Pharma Completes Enrollment in Eye Disease Study

2018-09-05 zacks
Horizon Pharma plc ((HZNP - Free Report) announced early completion of enrollment for the confirmatory phase III study of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED). The OPTIC study enrolled 83 patients at 13 sites across the United States, Germany and Italy.
CELGZ GILD LGNZZ CELG LGND LGNYZ LGNXZ HZNP LGNDZ

55
Tracking John Paulson's Paulson & Company Portfolio - Q2 2018 Update

2018-09-02 seekingalpha - 3
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking John Paulson’s Paulson & Company Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
AKRX VST TWX AU ENL SHPG HAWK VIAB AABA DST OSG.WI AEM INSW MITL AGG SYMX AET FOX TMUSP TMUS RGORF BKD GOLD UTX 2840 TWC OGISD NSW OGSRW MDT SES CZR OGSWW OGISZ XLGLF QCOM INSW.WI FOXA OGSBW ENDP NMRK XL CTL RRS GLD AULGF OSG VRX ODP AGN EGN MON HZNP OSGB DISH OVSPW CMCSA CACQ COL GOLD OVSPA OVSPD VSTE THM BHS

203
Stocks To Watch: Tesla Twist And Retail Rally

2018-08-25 seekingalpha - 2
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
ROP JAPSY TYEKF GES AOBC TWX ANF AMBA CRM WMT RGR DLTR JWN DSW AMZN SCVL CATO AEO DKS BOX ALNPF NWY HSY AMC TMUS HAIN BBY AKCA MHH CZR JT IONS ALNPY FLL GRVY MSFT LVS BA GCO MGM WSM TIF VAC TM ULTA IBKR NFLX RRR VMW ATVI PPDF GDEN LULU HEI AMTD HZNP SONO EA COTV WYNN CWK XNET COST M DEST VSTO TGT S SCHW JPM DL ETFC DG TSLA ARLO URBN 9202 FIVE ILG BYD

 
Horizon Pharma (HZNP) Boasts Robust Pipeline Amid Competition

2018-08-22 zacks
We issued an updated report on Horizon Pharma plc (HZNP - Free Report) on Aug 20.
MRK HZNP

 
Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise

2018-08-09 zacks
Horizon Pharma plc (HZNP - Free Report) reported better-than-expected results for the second quarter of 2018. Following the news, the company’s shares went up 10.7%. Horizon Pharma’s stock price has increased 37.8% year to date against the industry’s fall of 4.6%.
SGEN VRTX GILD UCTI HZNP UCTT

 
Horizon Pharma plc (HZNP) CEO Timothy Walbert on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good morning, and thank you for standing by. Welcome to the Horizon Pharma plc Second Quarter 2018 Earnings Conference Call. As a reminder, today’s conference call is being recorded.
HZNP

3
Horizon Pharma (HZNP) Tops Q2 Earnings and Revenue Estimates

2018-08-08 zacks
Horizon Pharma (HZNP - Free Report) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.
VREX ELY IPGP RYB HZNP

 
Horizon Pharma plc 2018 Q2 - Results - Earnings Call Slides

2018-08-08 seekingalpha
The following slide deck was published by Horizon Pharma plc in conjunction with their 2018 Q2 earnings call.
HZNP

 
HZNP / Horizon Pharma plc HZNP-10-Q-20180630 (Quarterly Report)

2018-08-08 sec.gov
hznp-10q_20180630.htm UNITED STATES
HZNP

 
HZNP / Horizon Pharma plc 8-K (Current Report)

2018-08-08 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
HZNP

2
Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat

2018-08-06 zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) ) incurred a loss of $1.61 per share (excluding stock-based compensation expense), wider than the year ago loss of $1.07 per share and the Zacks Consensus Estimate of a loss of $1.54.
GILD MDCO HZNP ALNY SNY

1
Tyson Foods (TSN) Q3 Earnings Beat Estimates, Sales Up Y/Y

2018-08-06 zacks
Tyson Foods, Inc. (TSN - Free Report) posted third-quarter fiscal 2018 results, wherein earnings and sales improved year over year. The quarter’s performance benefited from growth in the Beef and Prepared Foods segments. Gains from buyouts and savings initiatives also drove the results. However, volumes in the Chicken and Pork segments were dismal owing to lower demand. In fact, for fiscal 2018, the company predicts volatile market conditions to persist for Pork and Chicken.
HELE TSNU SCI HZNP TSN CHEF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: G4617B105